Safety and tolerability of caspofungin acetate in the treatment of fungal infections

Transplant Infectious Disease

Volumn 4, Issue 1, 2002, Pages 25-30

  Sable, C A ^a   Nguyen, B Y T ^a   Chodakewitz, J A ^a   DiNubile, Mark J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Aspergillosis; Caspofungin; Echinocandin; Esophageal candiasis; Safety

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; CASPOFUNGIN; CYCLOSPORIN; ECHINOCANDIN; FLUCONAZOLE; TACROLIMUS; UNCLASSIFIED DRUG;

ARTICLE; ASPERGILLOSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; MAJOR CLINICAL STUDY; MYCOSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT;

ANTI-BACTERIAL AGENTS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CLINICAL TRIALS, PHASE III; DOUBLE-BLIND METHOD; DRUG APPROVAL; DRUG TOLERANCE; FEVER; HEADACHE; HUMANS; IMMUNOCOMPROMISED HOST; MYCOSES; PEPTIDES; PEPTIDES, CYCLIC; PHLEBITIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0036073337     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.2002.01004.x     Document Type: Article

References (13)

1. Current and future antifungal therapy: New targets for antifungal agents
2. Discovery of novel antifungal (1,3)-β-D-glucan synthase inhibitors
3. A randomized, double-blind, multicenter trial of MK-0991, an echinocandin antifungal agent, versus amphotericin B for the treatment (Tx) of oropharyngeal (OPC) and esophageal (EC) candidiasis in adults
4. A randomized, double-blind, multicenter trial of MK-0991 (L-743872) versus amphotericin B (AMB) in the treatment of Candida esophagitis in adults
5. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis
6. Efficacy of caspofungin as salvage therapy in invasive aspergillosis (IA) compared to standard therapy in a historical cohort
7. Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine
8. Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872)
9. Single-and multiple-dose pharmacokinetics of the antifungal agent MK-0991 in man
10. Disposition of MK-0991, a potent antifungal agent, in rats with acute renal failure
11. Single dose caspofungin pharmacokinetics in healthy elderly subjects
12. A phase 1 study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender and the use of a loading dose regimen
13. Drug interactions between caspofungin and tacrolimus